Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic–induced necroptosis
Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering
Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering
View: Text | PDF
Research Article Cell biology Oncology

Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic–induced necroptosis

  • Text
  • PDF
Abstract

Caspase-8 (CASP8) is one of the most frequently mutated genes in head and neck squamous carcinomas (HNSCCs), and CASP8 mutations are associated with poor survival. The distribution of these mutations in HNSCCs suggests that they are likely to be inactivating. Inhibition of CASP8 has been reported to sensitize cancer cells to necroptosis, a regulated cell death mechanism. Here, we show that knockdown of CASP8 renders HNSCCs susceptible to necroptosis by a second mitochondria-derived activator of caspase (SMAC) mimetic, birinapant, in combination with pan-caspase inhibitors Z-VAD-FMK or emricasan and radiation. In a syngeneic mouse model of oral cancer, birinapant, particularly when combined with radiation, delayed tumor growth and enhanced survival under CASP8 loss. Exploration of molecular underpinnings of necroptosis sensitivity confirmed that the level of functional receptor-interacting serine/threonine protein kinase 3 (RIP3) determines susceptibility to this mode of death. Although an in vitro screen revealed that low RIP3 levels rendered many HNSCC cell lines resistant to necroptosis, patient tumors maintained RIP3 expression and should therefore remain sensitive. Collectively, these results suggest that targeting the necroptosis pathway with SMAC mimetics, especially in combination with radiation, may be relevant therapeutically in HNSCC with compromised CASP8 status, provided that RIP3 function is maintained.

Authors

Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering

×

Figure 3

Knockdown of CASP8 enhances the radiosensitizing effects of birinapant and Z-VAD-FMK through induction of necroptosis.

Options: View larger image (or click on image) Download as PowerPoint
Knockdown of CASP8 enhances the radiosensitizing effects of birinapant a...
MOC1 control and shCasp8 cells were treated with radiation (X [2, 4, and 6 Gy]), birinapant (B [125 nmol/L in A; 250 nmol/L in B–D]), Z-VAD-FMK (Z [5 μmol/L]), necrostatin-1s (N [10 μmol/L]), or the combinations as indicated. (A) Representative images of clonogenic survival assays for the X (4 Gy) conditions. Twenty-four hours after treatments, drug dilutions were washed out, and colonies were allowed to form for 5 days, after which they were stained and counted. Surviving colony counts were normalized to nontreated cells (cells treated with no drugs) of each radiation dose from the same experiment. Log10 of surviving fractions were plotted. All treatments were carried out in triplicates. One-way ANOVA with post hoc Bonferroni-corrected t test was used for statistics. *P < 0.05 and **P < 0.001, when comparing surviving fractions following X+B treatments between control and shCASP8 cells. ǂP < 0.05, when comparing surviving fractions following X+B+Z treatments between control and shCasp8 cells. ƒP < 0.05, when showing reversal of death upon addition of N to X+B+Z for the control cells. ƞP < 0.001, when showing reversal of death upon addition of N to X+B+Z for the control cells. ƷP < 0.001, when showing reversal of death upon addition of N to X+B+Z for the shCasp8 cells. Symbols are placed at the radiation doses they refer to. Please refer to Supplemental Figure 6 and Supplemental Table 6 for more detailed analysis. (B) Annexin V-APC/SytoxBlue staining was performed 24 hours after treatments. Cells were treated with X (6 Gy). Percentage of annexin V positivity was used as a measure to assess cell death. All treatments were carried out in triplicates. (C) Cell viability was assessed using CellTiter-Glo. Values normalized to nontreated cells from the same experiment to calculate percentage of cell density. All treatments were carried out in replicates of 4. X (6 Gy) data are shown for simplicity. A more detailed version can be found in Supplemental Figure 7; 1-way ANOVA with post hoc Bonferroni-corrected t test was used for statistics. *P < 0.05, **P < 0.001 for the indicated pairwise comparisons for B and C. (D) Whole-cell lysates were collected 24 hours after treatments (with X at 6 Gy) and subjected to Western blot analysis for the indicated key cell death markers; β-actin was used as loading control. All experiments detailed above were repeated 3 times with similar results.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts